Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix, Oncimmune EarlyCDT Lung

Biodesix has commercially launched Oncimmune's EarlyCDT Lung test in the US, under a commercialization agreement the two firms announced last year. Marketed under Biodesix's Nodify Lung brand, the new Nodify CDT test is designed to assist physicians to identify patients with lung nodules at high risk of lung cancer.

The assay joins Biodesix's existing Notify XL2 test for low-risk lung nodule detection, and, according to Oncimmune, both tests will now be offered together as the Nodify Lung Nodule Risk Assessment strategy, with physicians able to order the two assays from a single blood draw.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.